Corpus Intelligence IC Memo — ST VINCENTS BIRMINGHAM 2026-04-26 03:43 UTC
IC Memo — ST VINCENTS BIRMINGHAM
Investment Committee Memorandum | AL | 399 beds | Grade C | EBITDA uplift $35.3M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

ST VINCENTS BIRMINGHAM

CCN 010056 | JEFFERSON, AL | 399 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

ST VINCENTS BIRMINGHAM is a 399-bed suburban community hospital in JEFFERSON, AL with $480.0M in net patient revenue and a -5.5% operating margin. The hospital serves a payer mix of 19.2% Medicare, 9.7% Medicaid, and 71.2% commercial.

Thesis: Undervalued. Our ML models identify $35.3M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -5.5% to 1.9% (+736bps).

Net Revenue HCRIS$480.0M
Current EBITDA COMPUTED$-26.2M
Operating Margin COMPUTED-5.5%
Occupancy HCRIS67.0%
Revenue / Bed COMPUTED$1.2M
Net-to-Gross HCRIS19.5%
Distress Probability ML45.1%

2. Market Context & Competitive Position

115
AL Hospitals
-8.5%
State Median Margin
23
Comparable Hospitals

AL has 115 Medicare-certified hospitals with a median operating margin of -8.5%. The target's margin of -5.5% places it above the state median. Among 23 size-comparable peers (200-798 beds), the median margin is -4.4%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (200-798), prioritizing same-state peers. 23 hospitals in the comp set.

HospitalStateBedsRevenueMargin
ST VINCENTS BIRMINGHAM (Target)AL399$480.0M-5.5%
THE CHILDRENS HOSPITAL OF ALABAL351$839.5M5.8%
GRANDVIEW MEDICAL CENTERAL404$615.4M14.2%
DCH REGIONAL MEDICAL CENTERAL372$601.9M-11.2%
BAPTIST MEDICAL CENTER SOUTHAL348$595.4M-4.8%
MOBILE INFIRMARY MEDICAL CENTEAL593$542.2M3.1%
SOUTHEAST HEALTH MEDICAL CENTEAL353$427.1M-4.4%
EAST ALABAMA MEDICAL CENTERAL297$399.6M-6.5%
USA HEALTH UNIVERSITY HOSPITALAL242$348.5M-6.4%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $35.3M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$10.1M+210bp18mo
Cost to Collect4.5%2.5%$9.6M+200bp12mo
Denial Rate Reduction12.0%6.5%$9.5M+198bp12mo
A/R Days Reduction5200.0%3800.0%$5.8M+122bp9mo
Clean Claim Rate88.0%96.0%$307K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$10.1M
Cost to Collect
$9.6M
Denial Rate Reduction
$9.5M
A/R Days Reduction
$5.8M
Clean Claim Rate
$307K
Total EBITDA Uplift$35.3M
Current EBITDA$-26.2M
+ RCM Uplift+$35.3M
Pro Forma EBITDA$9.2M
Current Margin-5.5%
Pro Forma Margin1.9%
WC Released (1x)$18.4M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-40.3M$180.7M0.00x-100.0%
Base (11x exit)10.0x11.0x$-40.3M$185.7M0.00x-100.0%
Bull Case9.0x11.0x$-36.2M$289.3M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-36.2M$304.8M0.00x-100.0%
Bear Case11.0x10.0x$-44.3M$17.1M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-44.3M$4.5M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 23 hospitals with 200-798 beds
  • Same-state prioritization (n=24)
  • Comp margins: P25=-10.1% / P50=-4.4% / P75=1.4%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.